News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,172 Results
Type
Article (41812)
Company Profile (329)
Press Release (663031)
Section
Business (210131)
Career Advice (2075)
Deals (36572)
Drug Delivery (96)
Drug Development (82796)
Employer Resources (171)
FDA (16478)
Job Trends (15357)
News (355390)
Policy (33819)
Tag
Academia (2574)
Alliances (51085)
Alzheimer's disease (1247)
Approvals (16409)
Artificial intelligence (140)
Bankruptcy (362)
Best Places to Work (11672)
Biotechnology (214)
Breast cancer (122)
Cancer (1110)
Cardiovascular disease (102)
Career advice (1737)
Cell therapy (238)
Clinical research (65786)
Collaboration (395)
Compensation (202)
COVID-19 (2601)
C-suite (96)
Data (1135)
Diabetes (154)
Diagnostics (6224)
Earnings (86506)
Employer resources (149)
Events (112340)
Executive appointments (318)
FDA (17026)
Funding (359)
Gene therapy (188)
GLP-1 (611)
Government (4445)
Healthcare (18851)
Infectious disease (2686)
Inflammatory bowel disease (110)
Interviews (319)
IPO (16580)
Job creations (4051)
Job search strategy (1487)
Layoffs (433)
Legal (8318)
Lung cancer (172)
Manufacturing (185)
Medical device (13259)
Medtech (13264)
Mergers & acquisitions (20065)
Metabolic disorders (420)
Neuroscience (1531)
NextGen Class of 2024 (6626)
Non-profit (4512)
Northern California (1489)
Obesity (242)
Opinion (203)
Patents (105)
People (58235)
Pharmaceutical (93)
Phase I (20346)
Phase II (28952)
Phase III (21715)
Pipeline (460)
Postmarket research (2644)
Preclinical (8679)
Radiopharmaceuticals (241)
Rare diseases (229)
Real estate (6240)
Regulatory (22368)
Research institute (2358)
Resumes & cover letters (358)
Southern California (1309)
Startups (3712)
United States (13673)
Vaccines (568)
Weight loss (183)
Date
Today (1)
Last 7 days (675)
Last 30 days (3594)
Last 365 days (36220)
2024 (33270)
2023 (40628)
2022 (51797)
2021 (56331)
2020 (54796)
2019 (47402)
2018 (35771)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (199)
Asia (39992)
Australia (6395)
California (3356)
Canada (1301)
China (257)
Colorado (150)
Connecticut (156)
Europe (85149)
Florida (462)
Georgia (116)
Illinois (348)
Indiana (204)
Kansas (96)
Maryland (581)
Massachusetts (2654)
Michigan (159)
Minnesota (274)
New Jersey (972)
New York (968)
North Carolina (720)
Northern California (1489)
Ohio (139)
Pennsylvania (852)
South America (1157)
Southern California (1309)
Texas (475)
Washington State (369)
705,172 Results for "xeris pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
Xeris Biopharma Holdings, Inc. announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris’ XeriSol™ technology for use in Beta Bionics’ proprietary bi-hormonal pump and pump systems.
May 6, 2024
·
6 min read
BioMidwest
Xeris to Participate in the Jefferies Global Healthcare Conference
Xeris Biopharma Holdings, Inc. today announced that members of its senior management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6 at 2:00pm Eastern Time.
May 30, 2024
·
1 min read
BioMidwest
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - April 03, 2024
Xeris Biopharma Holdings, Inc. announced that on April 1, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 103,000 shares of its common stock to 18 new employee under Xeris’ Inducement Equity Plan.
April 3, 2024
·
2 min read
Press Releases
Xeris Biopharma Reports Third Quarter 2024 Financial Results
November 8, 2024
·
11 min read
Business
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
Xeris Biopharma Holdings, Inc. announced financial results for the first quarter ended March 31, 2024 and recent events.
May 9, 2024
·
10 min read
BioMidwest
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Biopharma Holdings, Inc. announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 11:00 am Eastern Time.
April 2, 2024
·
1 min read
Press Releases
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
October 31, 2024
·
1 min read
Business
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
Xeris Biopharma Holdings, Inc. announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024.
May 2, 2024
·
2 min read
BioMidwest
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 05, 2024
Xeris Biopharma Holdings, Inc. announced that on January 2, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 130,000 shares of its common stock to 18 new employee under Xeris’ Inducement Equity Plan.
January 5, 2024
·
2 min read
Drug Development
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
Xeris Biopharma Holdings today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism.
May 30, 2024
·
10 min read
1 of 70,518
Next
